Mediwound Ltd (MDWD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mediwound Ltd (MDWD) has a cash flow conversion efficiency ratio of -0.044x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.60 Million) by net assets ($59.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mediwound Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Mediwound Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MDWD current and long-term liabilities for a breakdown of total debt and financial obligations.
Mediwound Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mediwound Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
High Tide Inc
NASDAQ:HITI
|
0.042x |
|
Azkoyen
MC:AZK
|
0.141x |
|
Rockfields Property Indonesia Pt
JK:ROCK
|
0.034x |
|
Clearwater Paper Corporation
NYSE:CLW
|
0.006x |
|
EIH Associated Hotels Limited
NSE:EIHAHOTELS
|
0.023x |
|
Bell Equipment Limited
JSE:BEL
|
0.183x |
|
Hoang Huy Investment Services JSC
VN:HHS
|
-0.019x |
|
One Stop Systems Inc
NASDAQ:OSS
|
-0.130x |
Annual Cash Flow Conversion Efficiency for Mediwound Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Mediwound Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Mediwound Ltd (MDWD) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $31.15 Million | $-13.62 Million | -0.437x | -32.03% |
| 2023-12-31 | $31.59 Million | $-10.46 Million | -0.331x | +69.58% |
| 2022-12-31 | $10.91 Million | $-11.88 Million | -1.089x | -155.96% |
| 2021-12-31 | $-4.58 Million | $-8.92 Million | 1.946x | +305.23% |
| 2020-12-31 | $7.27 Million | $-6.89 Million | -0.948x | -273.51% |
| 2019-12-31 | $15.17 Million | $8.29 Million | 0.546x | +140.34% |
| 2018-12-31 | $8.97 Million | $-12.15 Million | -1.355x | +20.80% |
| 2017-12-31 | $9.62 Million | $-16.45 Million | -1.710x | +19.18% |
| 2016-12-31 | $7.77 Million | $-16.45 Million | -2.116x | -153.42% |
| 2015-12-31 | $23.47 Million | $-19.60 Million | -0.835x | -117.08% |
| 2014-12-31 | $42.87 Million | $-16.49 Million | -0.385x | -178.22% |
| 2013-12-31 | $-19.80 Million | $-9.74 Million | 0.492x | +262.63% |
| 2012-12-31 | $15.63 Million | $-4.73 Million | -0.302x | -- |
About Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more